Anebulo Pharmaceuticals Inc Stock Price, News & Analysis

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) has announced a PIPE financing agreement to sell 2,264,650 common shares and warrants to institutional accredited investors at a price of $2.935 per share. The accompanying warrants allow for the purchase of additional shares at $4.215, exercisable immediately and expiring in five years. Proceeds from this financing will be used to advance the development of ANEB-001 and for general corporate purposes. The closing of the deal is expected around September 29, 2022, pending customary conditions.

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced promising interim results from its Phase 2 clinical trial evaluating ANEB-001 for acute cannabinoid intoxication (ACI). In the trial, 10 mg and 30 mg doses of ANEB-001 significantly reduced THC-induced feelings of being high and body sway compared to placebo, while higher THC doses were administered. The study aims to optimize the drug's dosage and effectiveness, with ongoing evaluation of delayed dosing to simulate real-world scenarios. Anebulo anticipates that ANEB-001 could alleviate ACI symptoms and reduce healthcare burdens.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) is set to host its inaugural R&D Day on September 26, 2022, at the Nasdaq MarketSite in New York City, from 10:00 a.m. to 12:30 p.m. (ET). The event will also be webcast live on the Company’s website. Interested attendees can register via email. Anebulo is focused on developing solutions for acute cannabinoid intoxication and substance abuse disorder, with its lead product candidate, ANEB-001, in Phase 2 trials.

Anebulo Pharmaceuticals (Nasdaq: ANEB) reported its financial results for the fourth quarter and full year ended June 30, 2022. The company showed a reduced net loss of $2.3 million in Q4 compared to $29.1 million for the same period in 2021. Operating expenses for FY2022 increased to $6.8 million from $3.6 million in FY2021. Notably, Anebulo announced positive topline data from Part A of its Phase 2 trial for ANEB-001, which aims to treat acute cannabinoid intoxication. The company plans further development, including an R&D Day on September 26, 2022, to discuss future strategies.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) will host its first R&D Day on September 26, 2022, in New York City. CEO Simon Allen, along with senior executives including Founder Dr. Joseph Lawler and CSO Dr. Ken Cundy, will present updates on the company's progress, particularly on the Phase 2 study of product candidate ANEB-001. This candidate aims to address acute cannabinoid intoxication. Institutional investors and analysts are invited to register via email as seating is limited.

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced positive topline results from Part A of its Phase 2 clinical trial for ANEB-001, targeting acute cannabinoid intoxication (ACI). The trial included 60 subjects and demonstrated a significant reduction in feelings of being high, with only 10% in the 50 mg group and 30% in the 100 mg group compared to 75% in the placebo group (p < 0.0001). ANEB-001 was well tolerated, with mild side effects noted. The company plans to initiate Part B by Q3 2022 and is collaborating with the FDA for further studies on dosing optimization.

Anebulo Pharmaceuticals (NASDAQ: ANEB) announces it will release topline data from Part A of its Phase 2 study of ANEB-001 on July 5. The study involves sixty healthy subjects exposed to THC, aiming to evaluate ANEB-001 as a treatment for acute cannabinoid intoxication (ACI). CEO Simon Allen stated that the results will inform the next steps in the drug's development, emphasizing ANEB-001 as a leading antidote for ACI, which currently lacks FDA-approved treatments. This trial is conducted in the Netherlands by the Centre for Human Drug Research.

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) has appointed Dr. Kenneth Cundy as the new Chief Scientific Officer. Dr. Cundy brings over 30 years of experience in drug development, having contributed to significant therapeutic innovations including Gilead's tenofovir. His extensive background includes over 50 U.S. patents and experience with FDA regulations. CEO Simon Allen emphasized that Dr. Cundy's expertise aligns well with advancing their lead product, ANEB-001, through clinical trials for acute cannabinoid intoxication, an area of increasing medical need.

Anebulo Pharmaceuticals (ANEB) reported financial results for Q3 2022, enrolling all 60 subjects in Part A of a Phase 2 clinical trial in the Netherlands. The firm expects to release top-line data by June 30, 2022. Financial highlights include a net loss of $1.9 million, or $(0.08) per share, against a loss of $0.6 million in Q3 2021. Operating expenses rose to $1.9 million from $0.6 million year-over-year. As of March 31, 2022, the company's cash and equivalents totaled $16.5 million.